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Objective: To provide an overview of the utility of flow cytometry for phenotyping of 
acute leukaemias and selection of monoclonal antibodies.
Data sources: The literature review was obtained through internet, journals and 
chapters in the relevant books.
Data selection: Relevant articles and chapters on immunophenotyping of acute 
leukaemias were selected from respected international journals and books in the field 
of haematology and were reviewed. 
Data extraction and synthesis: Complete articles relevant to the topic were selected 
and reviewed and the necessary information extracted for this review. 
Conclusions: Flow cytometry has been used extensively in recent years to characterise 
haemopoeitic malignancies and done routinely in the developed world. This technique 
has greatly improved the diagnosis and classification of haemopoeitic malignancies 
and has been recommended by World Health Organisation classification (WHO) of 
tumours of haemopoeitic and lymphoid tissue. Application of flow cytometry for the 
diagnosis of leukaemias has been recently introduced in Kenya and is currently being 
undertaken in research using limited but appropriate panels of monoclonal antibodies. 
It is hoped that findings of this research will inform the use of flow cytometry as an 
ancillary diagnostic technique in our resource-constrained set up.  
INTRODUCTION
Flow cytometry which is a method of detecting 
membrane, cytoplasmic or nuclear antigens in 
cells produces rapid measurements of physical 
characteristics of cells suspended in a moving fluid 
stream. As many as 10,000 cells can be analysed per 
second. Currently in most of the developing countries, 
characterisation and classification of leukaemias is 
done by morphological and cytochemical analysis 
of cells in peripheral blood and bone marrow. 
With advances in medicine, flow cytometry has 
become an essential aid for accurate diagnosis, sub-
classification and prognostication of leukaemias and 
lymphomas. It is more sensitive and less subjective 
than morphology in analysing leukaemic cases. The 
World Health Organisation (WHO) classification of 
tumours of haemopoeitic and lymphoid tissue relies 
not only on morphology of the tumours but also on 
immunophenotyping, cytogenetics and molecular 
genetics for as an accurate diagnosis (1). 
FLOW CYTOMETRY
The concept of flow cytometry has been there for more 
than 50 years and cell counters have been used for 
25 years. The emergence of fluorescence detectors in 
the new generation of cytometers greatly improved 
their utility. Flow cytometry is efficient, sensitive 
and accurate giving more reproducible results than 
manual techniques. Multiple specimens can be 
analysed with a panel of 3-10. Testing is rapid and up 
to 10,000 cells can be analysed in one second. 
 Flow cytometry is highly sensitive making it 
possible to detect very small numbers of neoplastic 
cells. This is especially useful in detecting small 
numbers of leakaemic cell in the bone marrow, as a 
way of assessing the minimal residual disease after 
treatment of leukaemias. 
 The major limitations of flow cytometry are the 
high costs of instruments and reagents, specialised 
skills and experience required to perform the tests and 
sometimes difficulties of correlating the morphology 
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with the markers obtained in flow cytometry. However, 
with the recent increase in specific monoclonal 
antibodies and fluorochromes, and the emergence 
of four to six colour analysers, the specificity of flow 
cytometry has markedly improved. 
MONOCLONAL ANTIBODIES
A wide array of monoclonal antibodies is available 
for flow cytometry. Diagnosis of leukaemia is made 
using panels of monoclonal antibodies. This panel 
requires careful selection as it is the most important 
step towards diagnosis of leukaemia. It should be 
large enough to diagnose and subtype most of the 
leukaemias but should also be limited so as to be cost 
effective. These monoclonal antibodies are directed 
against the following category of antigens: 
Lineage associated antigens: The antibodies are 
directed against these antigens and they help in 
the identification of the lineage of leukaemic cells 




B-cell CD10, CD19, CD20, CD21, CD22, 
CD23, CD24, CD79, CD138, 
 immunoglobulin
T-cell CD1, CD2, CD3, CD4, CD5 
CD7, CD8, CD45RA, CD45RO, 
TCR
NK cell CD16, CD56, CD57
Myeloid CD13, CD14, CD15, CD33, 
CD117, anti-MPO
Monocytic CD11b, CD11c, CD14, CD64
Erythroid Glycophorin A
Megakaryocytic CD41, CD61
Immature cell antigens: These include CD10, CD34, 
CD117, Tdt. The presence of these markers usually 
indicates a haematological neoplasm. 
Pan-leucocyte antigen: CD45 is the pan leucocyte 
marker. Side scatter properties in conjunction with 
CD45 expression is helpful in differential diagnosis of 
different leukaemia sub types. In the majority of acute 
leukaemias, there is low side scatter and moderate 
expression of CD45. In the last few years, CD45 has 
been used for resolving leucocyte populations and 
help in accurate gating. 
SELECTION OF PANEL OF MONOCLONAL 
ANTIBODIES
Because of the high cost associated with monoclonal 
antibodies, judicious choice of a panel of monoclonals 
is recommended. Factors taken into consideration 
include the type of laboratory, workload of leukaemic 
samples, technical expertise available, number of 
antibodies used in the panel and others like indication 
for immunophenotyping (initial diagnosis, sub 
typing, follow-up studies, and detection of minimal 
residual disease). The type of flow cytometer (three or 
more colours) will also help determine the panel. 
APPROACHES TO PANEL SELECTION
General, comprehensive panel: This approach is used in 
laboratories where cost is not a constraint. It normally 
includes 40-45 monoclonal antibodies per panel. The 
advantage of this approach is a faster turn around 
time, with less labourious and additional staining 
rarely required. It provides extensive information 
and minimal judgement is required. The main 
disadvantage is the wastage of reagents (3). 
Two-tiered approach: In this approach a minimal 
screening panel gives basic initial information which 
is then followed by secondary/ specific panel chosen 
according to results obtained with the primary 
panel. The approach is more labourious and time 
consuming and may not necessarily be cost effective 
in all situations (3). 
Directed or targeted approach: It is based on the 
availability of other data such as morphologic and 
clinical information. This approach can be cost 
effective as one may use very few antibodies in the 
initial panel but can be dangerous if wrong clinical 
information is provided or a mistake has been made in 
reporting the morphology. Many a times, morphology 
could be subjective (3). 
Indication based approach: This was the approach 
used by the 2006 Bethesda International Consensus 
Conference. This is quite different and utilises a 
combination of lineage-sensitive panel of monoclonal 
antibodies, (B-cell, T-cell, myeloid, monocytic, plasma 
cells) which is based upon the clinical presentation 
and medical indication (4). 
RECOMMENDATIONS
Varying guidelines have been published by different 
working groups from different parts of the world for 
implementation of flow cytometry in leukaemias. 
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None of them have arrived at a consensus on the 
way to select an ideal panel of monoclonal antibodies 
required to analyse cases of acute leukaemias. 
It is possible to have an algorithm for chronic 
lymphoproliferative disorders but heterogeneity in 
the antigens and inconsistent antigen expression by 
the blasts makes it difficult to have the same in acute 
leukaemias. The British Committee for Standards in 
Haematology (BCSH) guideline by Bain et al (5) in 
2002 recommended that if the case is clearly myeloid 
(based on presence of auer rod and/or with positive 
for myeloperoxidase or Sudan Black B), then there 
is not much gained with immunophenotyping. But 
all other cases like acute lymphoblastic leukaemia 
(ALL), acute myeloid leukaemia (AML)-MO, AML-
M7, biphenotypic leukaemias should be diagnosed 
with flow cytometry. 
 The US-Canadian Consensus (3) was of the 
opinion that an initial core panel be used to identify 
the type of disease and the predominant cell lineage. 
This should be followed by a supplementary panel. It 
recommended CD2, CD5, CD7, CD10, CD13, CD14, 
CD19, CD33, CD34, HLA-DR and kappa/lambda to 
be used as the core panel. 
 The International Society for Advancement of 
Cytometry(ISAC) consensus meet in 2000 between 
US and European experts recommended CD3, CD7, 
CD10, CD14, CD19, CD33, CD34, CD45 and HLA-
DR be used as initial core panel along with at least 
one antibody of B-cell (CD20, CD22, CD79a, IgM), 
T-cell (CDla, CD2, CD4, CD5, CD8), myeloid (CDllb, 
CD15, CD64, CD117, anti-MPO), erythroid (CD36, 
CD71, glycophorin-A) and megakaryocytic (CD41, 
CD61) (6). 
 BCSH (2) recommended CD2, cCD3, CD10, 
CD13, CD19, cCD22, CD79a, CD1l7, anti-MPO and 
Tdt as first line panel. 
 The Latin-American consensus conference 
(7) advised usage of CD13, CD15, CD33, CD117, 
anti-MPO  (myeloid), CD10, CD19, CD79a, SIg, 
cytoplasmic kappa/lambda ( B lineage), CD2, CD3, 
CD7 (T lineage) and CD34, CD45, HLA-DR and Tdt 
be used. 
 In contrast, 2006 Bethesda International Consensus 
recommendations include a panel of antibodies which 
are sensitive to identify cells of particular lineage. 
It is suitable for acute leukaemias and also chronic 
lymphoproliferative disorders for primary evaluation. 
Combination of these markers are used (B cell, T cell, 
myeloid) for a particular medical indication. This 
guideline uses CD5, CD10, CD 19, CD20, CD45, kappa, 
lambda for B- cell, CD2, CD3, CD4, CD5, CD7, CD8, 
CD45, CD56 for T/NK cell, CD7, CDllb, CD13, CD14, 
CD15, CD16, CD34, CD45, CD56, CD117, HLA-DR for 
myelomonocytic cells and CD19, CD38, CD45, CD56 
for plasma cells. Based on the results of this primary 
panel, a more extensive lineage-specific panel of 
antibodies is used (4). 
 Another difficult area of diagnosis is acute 
biphenotypic leukaemia which has been described 
in detail by European group for the immunological 
characterisations of leukaemias (EGIL) (8). It has also 
been discussed by Campana and Behm (9). There are 
many limitations of all these recommendations. 
 After carefully considering all  these 
recommendations, we have made a panel of 
antibodies to evaluate acute leukaemias. This panel is 
wide and presently useful for research purpose. The 
information gathered from this research will help us 
select appropriate antibodies for diagnostic service 
which will be suitable for our setting.
CONCLUSION
Over the past twenty five years, immunophenotyping 
has become an essential tool for characterisation 
of acute leukaemias. Flow cytometry is one of the 
immunophenotyping techniques. Morphology along 
with cytochemistry may not give complete picture in 
all the cases and also could be subjective. They have 
to be complemented with flow cytometry for precise 
diagnosis. It is also important to remember that 
immunophenotyping is not a substitute to morphology 
which still remains the gold standard for all leukaemic 
cases. Every laboratory has to make their own panel 
of antibodies which suits them. This panel should 
have adequate number of antibodies so that it has 
high sensitivity. 
 In Kenya, taking into consideration various 
recommendations and experiences, a panel of suitable 
monoclonal antibodies to evaluate acute leukemias 
has been arrived at. This panel is wide and is currently 
being used in flowcytometry for research of acute 
leukaemias. The information gathered from ongoing 
research will help us to select an appropriate 
antibodies panel to serve as an ancillary test in the 
diagnosis of acute leukaemias within our resource 
constrained setting. 
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